Welcome to our dedicated page for Marker Therapeut news (Ticker: MRKR), a resource for investors and traders seeking the latest updates and insights on Marker Therapeut stock.
Marker Therapeutics Inc (MRKR) is a clinical-stage biotechnology company pioneering novel T cell-based immunotherapies and peptide vaccines for hematological cancers and solid tumors. This news hub provides investors and researchers with timely updates on MRKR's advancements in cancer treatment innovation.
Access comprehensive coverage of Marker Therapeutics' developments, including clinical trial progress, strategic partnerships, and regulatory milestones. Our curated news ensures you stay informed about key initiatives in immuno-oncology without promotional bias.
Key updates include MultiTAA technology advancements, NIH-funded research programs, financial disclosures, and scientific presentations. We track both therapeutic breakthroughs and operational developments critical for evaluating MRKR's position in the competitive biotech landscape.
Bookmark this page for streamlined access to verified Marker Therapeutics updates. For comprehensive analysis of MRKR's pipeline and market potential, visit Stock Titan regularly.
Marker Therapeutics (Nasdaq: MRKR) has been awarded a $2 million grant from the NIH Small Business Innovation Research program to support the clinical investigation of MT-601 in patients with non-Hodgkin's lymphoma (NHL) who have relapsed following anti-CD19 CAR T cell therapy. The grant will fund the nationwide multi-center Phase 1 APOLLO study, evaluating the safety and efficacy of MT-601, a multi-tumor associated antigen-specific T cell product.
The company has now received over $19 million in non-dilutive funding. Preliminary results from the APOLLO study show objective responses in all three study participants treated at City of Hope, with no cytokine release syndrome or immune effector cell associated neurotoxicity syndrome observed. This grant supports Marker's efforts to address the unmet medical need for patients who relapse after CD19-targeting CAR-T cell therapy.
Marker Therapeutics (Nasdaq: MRKR) reported first quarter 2024 financial results and business updates. The company highlighted continued clinical progress, noting promising results in its Phase 1 APOLLO study of MT-601 for lymphoma. Significant milestones include sustained complete responses in study participants and an official nonproprietary name 'neldaleucel' for MT-601. Financially, Marker saw a reduction in R&D and G&A expenses, narrowing its net loss to $2.4 million from $4.9 million year-over-year. Cash and cash equivalents stood at $11.3 million, expected to fund operations into Q4 2025.
FAQ
What is the current stock price of Marker Therapeut (MRKR)?
What is the market cap of Marker Therapeut (MRKR)?
